Apremilast for immune checkpoint inhibitor-associated psoriasis and psoriatic arthritis: A systematic review

We conducted a systematic review of Apremilast for treating immune checkpoint inhibitor-associated psoriasis and psoriatic arthritis.
Supplementary File 1. Search Strategy and Eligibility Criteria.
Supplementary File 2. Complete List of References.
Supplementary Table I. List of Included Studies, Characteristics of Psoriasis/Psoriasiform Eruption and Outcome after Apremilast Use.
Supplementary Table II & III. Risk of Bias Assessment of Included Studies.

我们对用于治疗免疫检查点抑制剂相关银屑病和银屑病关节炎的阿普列马斯特进行了系统综述。附件文件1：检索策略和纳入标准。附件文件2：参考文献完整清单。附件表I：纳入研究列表、银屑病/银屑病样皮疹的特征以及阿普列马斯特使用后的结果。附件表II和III：纳入研究的偏倚风险评估。